Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body weight-adjusted clopidogrel therapy in coronary artery disease
NL-OMON53494Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clopidogrel, prasugrel and aspirin in Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (3 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Platelet reactivity unit level and High on-treatment platelet reactivity. Started Apr 2023; status: recruiting.
02
Drugs
clopidogrelprasugrelaspirin
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON53494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53494.